Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results

Through two years, ranibizumab + PDT was more effective than PDT alone and had a low rate of associated adverse events.